Pune, India, Sept. 07, 2022 (GLOBE NEWSWIRE) — The global cCardiovascular drug market size is expected to reach USD 63.96 billion by 2026 and show a CAGR of 3.8% over the forecast period. The rising incidence of cardiovascular diseases will be one of the key growth drivers for this market over the next decade. According to the 2017 Global Burden of Disease Study, cardiovascular disease (CVD) is the most common chronic disease, killing approximately 17.8 million people annually. Of these, nearly 82% of deaths occur in low- and middle-income countries. The World Health Organization (WHO) estimates that 80% of CVD deaths are caused by heart attack and stroke. These diseases also impose a heavy economic burden. For example, the American Heart Association estimates that medical costs related to cardiovascular disease will reach $749 billion by 2035. Hence, there is an urgent need to find effective drugs to treat these conditions and increase the growth of cardiovascular drugs market.
Fortune Business Insights, through its report titled Cardiovascular Drugs Market Size, Share & Industry Analysis, By Drug Type (Antihypertensive, Antihyperlipidemic, Anticoagulant, Antiplatelet, Other), By Disease Indication (Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, Other ), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other) and Regional Forecast, 2019-2026,” provides a comprehensive analysis of the factors and dynamics expected to impact the share, size, and overall growth of the market during the forecast period. The report also provides an in-depth study of overall industry trends that will enable competitors in this market to make informed business decisions.
Request Sample – Cardiovascular Drugs Market Report
Key Industry Developments:
- November 2019: The US Food and…
